| Symbol | TLSA |
|---|---|
| Name | TIZIANA LIFE SCIENCES LTD |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9TH FLOOR,107 CHEAPSIDE, LONDON, EC2V 6DN, Bermuda |
| Telephone | +44 207495237 |
| Fax | — |
| — | |
| Website | https://www.tizianalifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001723069 |
| Description | Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohns Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products. Additional info from NASDAQ: |
Director CERRONE GABRIELE M 🟢 acquired 15.0K shares of Tiziana Life Sciences Ltd (TLSA) at $1.11 Transaction Date: Jun 12, 2026 | Filing ID: 069424
Read moreTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Read moreNew Form 3 - Tiziana Life Sciences Ltd <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 0001213900-26-060643 <b>Size:</b> 22 KB
Read moreTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Read moreNew Form NT 20-F - Tiziana Life Sciences Ltd <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001213900-26-050353 <b>Size:</b> 18 KB
Read moreTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Read moreTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06802328 | Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active S… | — | Non-Active Secondary Progressive Multiple Sclerosis | Available | — | — | ClinicalTrials.gov |
| NCT07688239 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, a… | Phase2 | ALS (Amyotrophic Lateral Sclerosis) | Not_Yet_Recruiting | 2026-07-25 | 2027-11-01 | ClinicalTrials.gov |
| NCT06489548 | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzhe… | Phase2 | Dementia | Recruiting | 2025-09-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT06868628 | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (M… | Phase2 | Multiple System Atrophy | Recruiting | 2025-05-19 | 2027-04-01 | ClinicalTrials.gov |
| NCT06890923 | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Scle… | Phase2 | Non-Active Secondary Progressive Multiple Sclerosis | Recruiting | 2025-03-04 | 2026-08-30 | ClinicalTrials.gov |
| NCT06292923 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Scleros… | Phase2 | Secondary Progressive Multiple Sclerosis | Active_Not_Recruiting | 2023-11-15 | 2026-10-01 | ClinicalTrials.gov |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | Phase2 | NSCLC | Unknown | 2023-03-15 | 2025-06-01 | ClinicalTrials.gov |
| NCT05028946 | A Study of Oral Foralumab in Participants With Moderate to Severely Active Croh… | Phase1 | Crohn's Disease | Withdrawn | 2022-05-01 | 2023-11-07 | ClinicalTrials.gov |
| NCT04983446 | In-patient COVID-19 Study of Intranasal Foralumab | Phase2 | Covid19 | Withdrawn | 2022-04-30 | 2022-12-30 | ClinicalTrials.gov |
| NCT05029609 | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Pr… | Phase1 | Primary Progressive Multiple Sclerosis | Withdrawn | 2021-10-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT06879067 | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human… | Phase1 | Safety | Completed | 2018-11-12 | 2020-11-09 | ClinicalTrials.gov |
| NCT03291249 | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients W… | Phase2 | NASH - Nonalcoholic Steatohepatitis | Withdrawn | 2017-12-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT03109886 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carc… | Phase2 | Hepatocellular Carcinoma | Completed | 2017-07-12 | 2019-06-20 | ClinicalTrials.gov |
| NCT01301391 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treate… | Phase2 | Malignant Thymoma | Terminated | 2011-02-02 | 2018-12-17 | ClinicalTrials.gov |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Phase2 | Thymic Carcinoma | Terminated | 2010-02-22 | 2018-12-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | NOT_YET_RECRUITING | NCT07688239 |
| Foralumab Nasal | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | NOT_YET_RECRUITING | NCT07688239 |
| Placebo | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06292923 |
| Foralumab | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06292923 |
| Foralumab Nasal | Other | Phase PHASE2 | Multiple System Atrophy | RECRUITING | NCT06868628 |
| Milciclib Maleate | Other | Phase PHASE2 | Malignant Thymoma | TERMINATED | NCT01301391 |
| Foralumab Nasal | Other | Phase PHASE2 | Multiple System Atrophy | RECRUITING | NCT06868628 |
| Milciclib Maleate | Other | Phase PHASE2 | Thymic Carcinoma | TERMINATED | NCT01011439 |
| Omeprazole 20mg | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | WITHDRAWN | NCT03291249 |
| placebo | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | WITHDRAWN | NCT03291249 |
| Foralumab | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | WITHDRAWN | NCT03291249 |
| Milciclib maleate | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT03109886 |
| Placebo | Other | Phase PHASE1 | Primary Progressive Multiple Sclerosis | WITHDRAWN | NCT05029609 |
| Intranasal Foralumab Solution | Other | Phase PHASE1 | Primary Progressive Multiple Sclerosis | WITHDRAWN | NCT05029609 |
| Placebo | Other | Phase PHASE2 | Covid19 | WITHDRAWN | NCT04983446 |
| Foralumab | Other | Phase PHASE2 | Covid19 | WITHDRAWN | NCT04983446 |
| Foralumab | Other | Phase PHASE1 | Crohn's Disease | WITHDRAWN | NCT05028946 |
| Milciclib Dose: 150 mg/day Mode of administration: oral | Other | Phase PHASE2 | NSCLC | UNKNOWN | NCT05651269 |
| Foralumab Nasal | Other | Phase PHASE1 | Safety | COMPLETED | NCT06879067 |
| Placebo | Other | Phase PHASE1 | Safety | COMPLETED | NCT06879067 |
| Foralumab TZLS-401 100 µg | Other | Phase PHASE2 | Non-Active Secondary Progressive Multiple Sclerosis | RECRUITING | NCT06890923 |
| Foralumab TZLS-401 50 µg | Other | Preclinical | Non-Active Secondary Progressive Multiple Sclerosis | AVAILABLE | NCT06802328 |
| Placebo | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | RECRUITING | NCT06292923 |
| Foralumab | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | RECRUITING | NCT06292923 |
| Foralumab TZLS-401 100 µg | Other | Phase PHASE2 | Dementia | RECRUITING | NCT06489548 |
| Foralumab TZLS-401 50 µg | Other | Phase PHASE2 | Dementia | RECRUITING | NCT06489548 |
| Foralumab Nasal | DRUG | Phase PHASE1 | Safety | COMPLETED | NCT06879067 |
| Foralumab TZLS-401 100 µg | DRUG | Phase PHASE2 | Non-Active Secondary Progressive Multiple Sclerosis | RECRUITING | NCT06890923 |
| Foralumab TZLS-401 50 µg | DRUG | Preclinical | Non-Active Secondary Progressive Multiple Sclerosis | AVAILABLE | NCT06802328 |
| Milciclib Dose: 150 mg/day Mode of administration: oral | DRUG | Phase PHASE2 | NSCLC | UNKNOWN | NCT05651269 |
| Intranasal Foralumab Solution | DRUG | Phase PHASE1 | Primary Progressive Multiple Sclerosis | WITHDRAWN | NCT05029609 |
| Placebo | DRUG | Phase PHASE1 | Safety | COMPLETED | NCT06879067 |
| Omeprazole 20mg | DRUG | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | WITHDRAWN | NCT03291249 |
| placebo | OTHER | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | WITHDRAWN | NCT03291249 |
| Foralumab | DRUG | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | RECRUITING | NCT06292923 |
| Milciclib maleate | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT03109886 |
| Milciclib Maleate | DRUG | Phase PHASE2 | Malignant Thymoma | TERMINATED | NCT01301391 |